35.98
+1.09(+3.12%)
Currency In USD
Previous Close | 34.89 |
Open | 34.85 |
Day High | 36.25 |
Day Low | 34.04 |
52-Week High | 130 |
52-Week Low | 6.76 |
Volume | 701,553 |
Average Volume | 957,406 |
Market Cap | 264.71M |
PE | 0.1 |
EPS | 356.28 |
Moving Average 50 Days | 27.95 |
Moving Average 200 Days | 21.79 |
Change | 1.09 |
If you invested $1000 in Tonix Pharmaceuticals Holding Corp. (TNXP) 10 years ago, it would be worth $0 as of June 30, 2025 at a share price of $35.98. Whereas If you bought $1000 worth of Tonix Pharmaceuticals Holding Corp. (TNXP) shares 5 years ago, it would be worth $0.09 as of June 30, 2025 at a share price of $35.98.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
GlobeNewswire Inc.
11 hours ago
CHATHAM, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company, today announced that it will be added to the broad-market Russell 3000® Index, wit
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025
GlobeNewswire Inc.
Jun 16, 2025 11:00 AM GMT
TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia: FDA PDUFA goal date of August 15, 2025 TNX-102 SL demonstrated statistically significant improvement in the pr
Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors
GlobeNewswire Inc.
Jun 13, 2025 11:00 AM GMT
Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix Medicines, acquisitio